ABSTRACT
ABSTRACT The prevalence of diabetes mellitus is increasing and is related to sedentary lifestyles and obesity. Many studies were published on the effect of lifestyle interventions on glucose regulation and delay the onset of diabetes in adults with impaired glucose tolerance (IGT) or prediabetes. This study aimed to investigate the role of lifestyle interventions in individuals with IGT or prediabetes using a meta-analytic approach. PubMed, Embase, and the Cochrane Central Register of Controlled Trials databases were searched from their inception up to January 2020 to select eligible randomized controlled trials (RCTs). The weighted mean difference (WMD; for fasting plasma glucose (FPG) and 2-hour plasma glucose (2hPPG)) or relative risk (RR; for the risk of diabetes) with 95% confidence interval (CI) were calculated for pooled effect estimates using the random-effects model. Thirteen RCTs involving 3376 individuals with IGT or prediabetes were selected for this meta-analysis. The results showed that lifestyle interventions were associated with lower FPG (WMD: -0.14; 95% CI: -0.24 to -0.05 mmol/L; p=0.004) and 2hPPG (WMD: -0.66; 95% CI: -1.12 to -0.20 mmol/L; p=0.005) in adults with IGT or prediabetes. Moreover, the risk of diabetes was significantly reduced in individuals who received lifestyle interventions (RR: 0.75; 95% CI: 0.60-0.95; p=0.015). Lifestyle interventions could help improve glucose dysregulation and prevent the progression of diabetes in adults with IGT or prediabetes. Further large-scale RCTs should be conducted to assess the effects of long-term lifestyle interventions on diabetic complications in adults with IGT or prediabetes.
ABSTRACT
Objective:To study the clinical efficacy of Chaihu Shugansan on non-alcoholic fatty liver（NAFLD） patients with liver stagnation and spleen deficiency syndrome and its effect on intestinal flora. Method:The study was a single-center， randomized，single-blind， placebo-controlled clinical study involving 80 patients with NAFLD treated from January 2019 to January 2020 at our hospital. They were divided into two groups （Chaihu Shugansan group，<italic>n</italic>=40） and control group （placebo group，<italic>n</italic>=40）. The two groups of patients were given lifestyle intervention as the basic protocol. The treatment group was orally given Chaihu Shugansan，and the control group was orally given placebo. The drugs were given twice in the morning and evening， 1 dose/time. Patients were followed up for 12 weeks. Before and after treatment，the efficady on liver steatosis was observed by abdominal ultrasound and transient elastography （Fibroscan）， levels of alanine aminotransferase（ALT），aspartate aminotransferase（AST），glutamyl transpeptidase（<italic>γ</italic>-GT），high density lipoprotein cholesterol（HDL-C），low density lipoprotein cholesterol（LDL-C），total cholesterol（TC），triglyceride（TG），interleukin（IL）-6，IL-1<italic>β</italic>，Toll-like receptor-4（TLR-4） in peripheral blood mononuclear cells（PBMCs） and intestinal flora were also detected. Result:There were 37 patients in the treatment group and 35 patients in the control group who finally completed the study protocol. The total effective rate of NAFLD in the treatment group（81.08%，30/37） was higher than that in the control group （68.57%，24/35）（<italic>Z</italic>=2.67，<italic>P</italic><0.05）. The treatment group was superior to the control group in reducing the levels of BMI，ALT，AST，TC，LDL-C，TG，<italic>γ</italic>-GT and increasing the level of HDL-C（<italic>P</italic><0.05）. The levels of pro-inflammatory cytokines（TNF-<italic>α</italic>，IL-1<italic>β</italic> and IL-6），the values of Controlled Attenuation Parameter（CAP），Liver Stiffness Measurement（LSM） and expression of TLR4 were down-regulated in the treatment group （<italic>P</italic><0.01）. In addition，the treatment group showed increase in the abundance of beneficial bacteria （<italic>Bifidobacterium</italic> and <italic>Lactobacillus</italic>） and inhibited the abundance of pathogenic bacteria （<italic>Enterobacter </italic>and<italic> Enterococcus</italic>） in the gut（<italic>P</italic><0.01）. Conclusion:In addition to the lifestyle intervention，Chaihu Shugansan can improve lipid metabolism and liver function，regulate intestinal flora and inhibit the level of inflammatory factors in patients with NAFLD.